SEMULOPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS RECEIVING CHEMOTHERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 20, 2012
app pub date -
May 11, 2012
filing date -
May 12, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to an ultra-low molecular weight heparin with an average molecular weight of 2000 to 3000 Daltons, an anti-FXa activity of about 160 U/mg and an anti-FIIa activity of about 2 U/mg, in particular semuloparin, for use as an antithrombotic agent for the prophylaxis of venous thromboembolism in cancer patients receiving chemotherapy for locally advanced or metastatic solid tumors, more specifically in patients receiving chemotherapy for locally advanced or metastatic pancreatic or lung cancer, or for locally advanced or metastatic solid tumors with a VTE risk score equal to or greater than 3.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully